PowerShares Dynamic Biotech & Genome ETF
Seattle Genetics’ 1Q16 Earnings: What Are Analysts Expecting?
Seattle Genetics is set to release its first-quarter 2016 earnings on April 28, 2016. Analysts estimate revenues of around $116 million for 1Q16.
Ionis Pharmaceuticals’ Valuation on May 23
Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases.
BioMarin Leads in the Market for Mucopolysaccharidoses Disorders
BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.
A Financial Overview of Sangamo Therapeutics in December 2018
In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.
Amgen: Analysts’ Recommendations on October 25
Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.
Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth
Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.
Biogen: Revenue Growth Is Expected in Q3
Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.
Ionis Pharmaceuticals’ Stock Performance in September
On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.
What Analysts Recommend for Ionis after Q2 2018
Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017.
Analysts Are Bullish on Sarepta Therapeutics
Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.
Analysts Have Mixed Opinions about Ionis
Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017.
How Ionis’s Spinraza Performed in 4Q17
Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is a drug designed for the treatment of spinal muscular atrophy.
Exploring Ionis’s 3Q17 Quarterly Revenue Trend
Ionis’s revenue sources include its commercial revenue and its research and development revenue under its collaborative agreements.
Gilead’s HIV and Hepatitis B Portfolio in 3Q17
Gilead’s portfolio As discussed previously, Gilead Sciences’ (GILD) portfolio includes antiviral drugs and other drugs. Whereas its antiviral products include those for hepatitis C, HIV, and hepatitis B infections, its other drugs include oncology, cardiovascular, inflammation, respiratory, and other products. HIV and hepatitis B products The above chart compares revenue for key HIV and hepatitis B products, which include […]
Myriad Genetics Saw Positive Results from GeneSight Trial
Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.
How Did Gilead’s Blockbuster Drug Harvoni Perform in 2Q17?
Harvoni is the top-selling drug in Gilead Sciences’ (GILD) portfolio. The drug is used for the treatment of genotype-1 hepatitis C virus (or HCV) infection.
What’s Ionis Pharmaceuticals’ Valuation?
Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.
What Drove Biogen Stock in 2Q17?
Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.
How Incyte’s Valuation Has Changed since 1Q17 Results
Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.
Changes in Ionis Pharmaceuticals’ Valuation after 1Q17
In 1Q17, Ionis Pharmaceuticals reported EPS (earnings per share) of $0.03 on revenue of $110.3 million, compared with EPS of -$0.52 on revenue of $36.9 million in 1Q16. In this series, we’ll look at its valuation since 1Q17.
A Look at Incyte’s Product Portfolio
Incyte has classified its oncology product portfolio into targeted anti-cancer therapies and immuno-oncology or immunotherapies.
What’s in Incyte’s Product Portfolio?
Incyte’s (INCY) product portfolio includes drugs for oncology as well as other areas.
Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix
While Neurocrine Biosciences (NBIX) invented and developed Elagolix until Phase 2 trials, it is currently being tested in Phase 3 trials by AbbVie (ABBV).
How Did Gilead’s Other Products Perform in 2Q16?
Gilead’s oncology portfolio includes Zydelig, which is used in combination with rituximab for the treatment of chronic lymphocytic leukemia (or CLL).
Incyte’s Product Portfolio Includes Potentially Lucrative Drugs
Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. It includes targeted therapies as well as immunotherapies.
Why Did BioMarin’s Share Price Tank after Brexit?
After the UK’s decision to withdraw from the EU, a sudden shock hit global markets on June 24. BioMarin lost ~11% of its value in the subsequent two days.
Inside Neurocrine Biosciences’ Analyst Recommendations in 2016
Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.
An Inside Look at Incyte’s Product Portfolio
Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. For oncology, its product portfolio includes targeted therapies as well as immunotherapies.
How Does Incyte’s Valuation Compare to Its Peers?
In this series, we’ll look at the performance of Incyte’s existing products and other factors that are driving the company’s revenues and valuation.
What Can We Expect from Seattle Genetics’s Adcetris in 1Q16?
Adcetris is an anti-CD30 monoclonal antibody that targets CD30, which is a marker for lymphoma.
How Does Incyte’s Valuation Compare to Peers?
Incyte, a Delaware-based biopharmaceutical company, is focused on developing and commercializing oncology products to cater to unmet medical needs.
BioMarin’s Vimizim Sales Were up by 195% in 2015
Vimizim contributed 26% to the top line of BioMarin Pharmaceutical in 2015. Meanwhile, the number of patients on Vimizim rose by 10% during 4Q15 over 3Q15.
Outlook for PBE’s Biotechnology Subsectors
PBE’s biotechnology subsector is trading below its 100-day moving average by 3.0%, but above it 20-day and 50-day averages by 1.3% and 4.0%, respectively.
The PowerShares Dynamic Pharmaceuticals ETF: PJP’s 2015 Performance
As of November 2015, PJP has outperformed the market, with a YTD return of 6.5%. The fund’s top ten holdings represent 52.41% of its total portfolio.
PJP and PBE Are Sectoral Smart Beta Funds
The PowerShares Dynamic Pharmaceuticals Portfolio ETF (PJP) is a smart beta fund that tracks the performance of the Dynamic Pharmaceutical Intellidex Index.